This process involves various other downstream molecules including Src/PKCα/NF-κB leading to the activation of transcriptional factors such as ETS or KLF that contribute to the aggressiveness of HER2-positive breast carcinoma phenotype and possibly cause feed-back resistance mechanism to HER2 targeted therapy. This evidence concerns the gene PRKCA and breast carcinoma.